The objectives of this study were to assess the pharmacokinetics and safety of subcutaneously delivered carboplatin in poloxamer 407 in rats. Carboplatin (5mg/rat) in 0.5ml poloxamer 407 (1.0 ml total volume) was administered subcutaneously in a right subcutaneous perineal incision in all 12 treatment rats. Three control rats received 1.0 ml of poloxamer 407. Total platinum was measured in plasma q24hrs from 0 to 168hrs. Protein-unbound platinum was measured in plasma at 168hrs. After sacrifice on day 7, total platinum was determined in wound bed muscle. Platinum concentrations in all samples were measured by ICP-MS. Wounds were visually assessed daily for 7 days. Perineal tissues (full wound bed including muscle, subcutis, skin) were assessed histologically and scored. Total platinum was detectable in plasma from 24 to 168 hrs. Total plasma platinum AUC and Cmax were 9,165.3 ng/mL•h and 129.4 ng/mL. Day 7 total platinum concentration in muscle was approximately 10-fold higher than total plasma platinum concentration. No unbound platinum was detected in plasma samples at 168 hours. No wound healing complications were detected at any time point, nor was tissue necrosis observed histologically. The results of this study suggest that subcutaneous carboplatin in poloxamer 407 can be used in vivo providing direct tissue exposure to carboplatin without significant local effects or systemic absorption and without wound healing complications.
Citation: Risselada M, Linder KE, Griffith E, Roberts BV, Davidson G, Zamboni WC, et al. (2017) Pharmacokinetics and toxicity of subcutaneous administration of carboplatin in poloxamer 407 in a rodent model pilot study. PLoS ONE 12(10): e0186018. https://doi.org/10.1371/journal.pone.0186018
Editor: Reza Yousefi, Shiraz University, ISLAMIC REPUBLIC OF IRAN
Received: April 27, 2017; Accepted: September 22, 2017; Published: October 5, 2017
This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Data Availability: All relevant data are within the paper and its Supporting Information files.
Funding: Funding for this study was through the 2014 NCSU, CVM intramural grant competition. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
There is a need for adjunctive means of local tumor control following surgery in anatomically challenging locations. One such tumor is an apocrine gland adenocarcinoma of the anal sac (AGASACA). These are commonly occurring, locally invasive tumors of the anal gland/anal sac complex. Due to the need to preserve local vital structures, residual tumor cells frequently remain following excision, leading to recurrence in 29% to 45% of patients [1–3]. Radiation therapy is currently recommended for postoperative treatment of residual microscopic disease, but is problematic due to the high cost and incidence of adverse effects, in particular locally occurring side effects . The role of systemic chemotherapy in local disease management is not well established, and such therapy is similarly associated with substantial acute adverse effects and cost. A chemotherapeutic agent that can be instilled into the wound bed at the time of surgery could considerably improve local disease control.
Poloxamer 407 is a nonionic polyoxyethylene-polyoxypropylene-polyoxyethylene (PEO-PPO-PEO) compound, which is unique in that it undergoes reverse gelatination, i.e. it changes from a liquid to a gel when it warms to temperatures higher than 25°C (including body temperature) [5,6]. This property has been shown to make poloxamer 407 a good carrier medium for prolonged local antifungal therapy . It has also shown to have sustained delivery in vivo of hydrophilic macromolecules after intramuscular injections in rats . It might show similar properties for subcutaneously administered chemotherapeutics. Prior studies have shown that poloxamer 407 by itself does not have adverse tissue effects in rats [7–9], and that poloxamer 407 will release 99% of the carboplatin as opposed to other carriers .
Carboplatin is a platinum chemotherapeutic agent that is used to systemically treat a variety of tumors, such as osteosarcoma and ASAGACA [2,3,11–16], and has been shown to be stable in poloxamer carriers [17,18] and fully release carboplatin  however information is not available about the stability of the combination of carboplatin and poloxamer gel in vivo or whether extensive local tissue damage occurs secondary to subcutaneous administration of this drug-poloxamer combination.
The objectives of this study were to 1) obtain pharmacokinetic data after perineal subcutaneous delivery of carboplatin in poloxamer copolymer gel, and 2) assess tissue safety and tissue effects of subcutaneously delivered carboplatin in poloxamer copolymer gel.
Our hypotheses were that in rats 1) carboplatin in poloxamer copolymer gel (carbo-poloxamer) instilled into perineal subcutaneous tissues will provide a sustained local presence of carboplatin leading to high local tissue concentrations but low plasma concentrations, and 2) carbo-poloxamer at a concentration of 5mg/ml does not cause local tissue necrosis.
Materials and methods
The carboplatin-poloxamer mix was compounded by mixing an equal volume of 10 mg/ml carboplatina (Carboplatin 10mg/mL, Hospiram Inc., Lake Forest, IL Carboplatina 10mg/ml (5 mg) with poloxamer copolymer gelb (0.5 mL) (Pluronic F127, poloxamer 407 (25% w/v;) 25% gel, Professional Compounding Centers of America, Houston, TX) under sterile conditions approximately 15 minutes prior to use.
The study was approved by the Institutional Animal Care and Use Committee at North Carolina State University (#14-080-B). Fifteen purpose bred female Sprague Dawley rats (Charles River, Wilmington, MA, US) were used in the study: three control rats without preplaced jugular vein catheters and two cohorts (n = 6) of treated study rats with preplaced jugular vein catheters. Animals were housed in a dedicated room with a 12:12 light: dark cycle in individual see through cages with a stainless steel lid with embedded filter with free access to water and food. Bedding consisted of Bed-o’Cobs ¼” (The Andersons, Inc Maumee, OH) and was changed on a weekly basis or earlier if needed. Environmental enrichment was provided and consisted of Nylabones and autoclaved cardboard tubes. Catheter maintenance was performed per vendor’s (Charles River, Wilmington, MA) recommendations and guidelines. This catheter was secured in place by skin clips and plugged with a blunt ended metal tip. Briefly: The distal end of the catheter could be retrieved after prepping the site and loosening or removing the clips. A heparin locking solution was used to prevent clotting and was removed prior to obtaining the sample. A fresh amount of locking solution was instilled after obtaining the sample and administering a volume of saline similar to the blood sample, after which the catheter was reinserted subcutaneously and secured in place. In all rats, a right perineal subcutaneous incision was made under general anesthesia (Isoflurane (Piranal Healthcare, Piranal Enterprises Ltd, Andhra Pradesh, India) in 100% O2 for box induction and mask maintenance), with a large enough subcutaneous pocket to hold 1ml of the compound, after which the incision was sutured routinely. Analgesia was provided by administration of meloxicam Q 24hrs (1mg/kg PO or SC)(Metacam, Boehringer Ingelheim, St Joseph, MO) the day prior, the day of and the day following surgery, and an additional injection of buprenorphine (Endo Pharmaceuticals, Spring Valley, NY) (0.03mg/kg SC) was provided prior to recovery.
Pharmacokinetics and local tissue toxicity
All rats in the two treatment cohorts received 1 ml of 5 mg/ml carboplatin-poloxamer mix instilled directly into the surgically created subcutaneous wound bed. The carboplatin-poloxamer mix was instilled in the subcutaneous pocket and the wound was sutured routinely in two layers after allowing the compound to gel in situ. In the treatment group, rats were divided in 2 cohorts: one cohort (n = 6) only received carboplatin-poloxamer (CP treatment cohort), the second cohort (n = 6) received carboplatin-poloxamer and had a microdialysis (μD) probe (LM-5 Linear microdialysis probe, BASi Inc., West Lafayette, IN) implanted for an unrelated study (CP-μD treatment cohort). This microdialysis probe was placed in the wound bed, secured with a suture in the wound and tunneled subcutaneously to exit dorsally in the cervical area. At 24 hours after surgery all probes were removed or cut flush at the cervical exit area if resistance was felt during removal. No dialysates were included or reported in this study. The control rats (n = 3) all received 1 ml of poloxamer copolymer gel only in the wound. In addition, two of the three control rats received a μD probe in the wound bed as described above, while the third control rat did not receive a μD probe. No control rat had a microdialysis sample collected at any time point.
The pre-placed jugular vein catheters were used to obtain daily blood samples (q24hrs) for total plasma Pt concentration (0.3 ml) at the time of wound assessment in all rats of all three treatment cohorts. On day 7, blood (3 ml) (all control and treatment rats) for the 168 hours total plasma Pt and unbound plasma Pt concentration as well as tissue samples (wound bed for total tissue platinum concentration [CP cohort]; wound bed, colon and contralateral perineal area for histology [all rats]) were taken after sacrificing the rat. No microdialysate samples were included in the study.
All plasma and muscle samples were stored at -80°C until analyzed for platinum (Pt) using a validated inductively-coupled plasma mass spectroscopy (ICP-MS) method as previously reported . Plasma samples were processed to measure total Pt at all time points and additionally protein-unbound Pt at 168 hours. Muscle samples were processed to measure total Pt as previously described . Briefly, muscle tissue and plasma samples were digested in concentrated (70%) HNO3 spiked with 200 ng/mL Iridium (Ir; analytical internal standard, Inorganic Ventures, Christiansburg, VA) for 60 min at 90°C. Deionized water was added to each sample for a final HNO3 concentration of 3.5%. Pt content in the sample was analyzed using ICP-MS (Agilent 7500cx, Agilent Technologies, Wilmington, DE, USA) and dedicated software (MassHunter Workstation Software v B.01.01). The results for muscle tissue are reported as Pt concentration per gram of tissue, which was adjusted for variability in the weight of each tissue. As per standard methods, the assumption made that the density of muscle tissue was 1 gram/mL, which allowed for continuity of results to be reported as ng/mL for both plasma and muscle. The lower limit of quantification (LLOQ) for total and unbound Pt in plasma and total Pt in tissues was 1 ng/mL.
Non-compartmental pharmacokinetic analyses of total Pt in the plasma was performed using commercially available software (Phoenix® WinNonlin® Software version 6.4, Certara, Princeton, NJ). The pharmacokinetic parameters estimated for total Pt in plasma after SC administration included the area under the curve (AUC) from time 0 to the last time point (AUClast) above the LLOQ, which was calculated using the log-linear trapezoidal method. The elimination rate constant (λz) was estimated from a minimum of three time points during the elimination phase. The remainder of reported parameters were generated using standard non-compartmental equations [21,22] The maximum plasma concentration (Cmax) and time to maximum plasma concentration (Tmax) were determined directly from the data.
Tissues samples were collected from the perineal implantation site and from the same anatomical area of the contralateral perineal side, and were fixed in 10% neutral-buffered formalin. Samples of the colon and/or pericolonic skeletal muscle were also collected. Tissues were processed routinely into paraffin for histology and 5 micrometer sections were stained with hematoxylin and eosin. A board-certified veterinary pathologist (KL) reviewed sections for histological lesions and the presence and severity of each of the following categories were individually subjectively scored: inflammation, necrosis, edema, hemorrhage, fibrin and fibrosis. A standard lesion severity scale was used for scoring, where a score of: 0 = no lesion, 1 = minimal, 2 = mild, 3 = moderate, 4 = marked .
Data was plotted and not normally distributed, therefore the total Pt in plasma was grouped by day and compared using a nonparametric Kruskal-Wallis ANOVA. The total plasma Pt AUC and total plasma Pt Cmax results between treatment groups were compared using a nonparametric Kruskal-Wallis ANOVA. A Bonferroni’s correction was used to correct for multiple comparisons. Due to evidence of heteroscedasticity in the residuals of the total plasma Pt Cmax, this data was log-transformed for statistical analysis.
The day 7 total Pt concentrations in plasma and muscle were compared using a nonparametric Wilcoxon test on the paired differences (total Pt in plasma minus total Pt in muscle). The same method was used to compare protein-bound and total plasma platinum. A repeated-measures ANOVA was used to assess differences over time, and between treatment groups.
A Fisher’s Exact test was used to test for homogeneity across the range of histological scores. The data was adjusted for multiple testing using the Bonferroni-Holm correction. Significance was set at p < 0.05 (with a corrected cut off of p = 0.006) for all analyses. Commercially available statistical software was used for all analyses (SAS version 9.3, SAS Institute Inc, Cary, NC).
The mean bodyweight of the treatment group rats was 376 ± 48.2 gram (range 310–495 gram). Each rat received 5 mg carboplatin total, for an approximate dose of 13.3 mg/kg BW (range to 10.1–16.1 mg/kg BW).
No wound dehiscence, pain on palpation or exudate was noted on any of the study days for any of the rats. Five out of 6 rats in the CP-μD treatment cohort, 6 out of 6 rats in the CP treatment cohort and 3 out of 3 control rats did not appear to have a significant tissue reaction macroscopically. The colonic and rectal wall macroscopically did not appear thickened, or inflamed in any of the 15 rats (12 treatment and 3 control rats).
Pharmacokinetic (PK) studies
No Total Pt was detectable in any of the plasma samples obtained prior to administering carboplatin. Total Pt was detected in all plasma samples from 24 to 168 hours and decreased significantly over time (p = 0.01) in both treatment cohorts (Fig 1). There was a significant difference in total Pt exposures in plasma between the two treatment cohorts (p = 0.03). The CP cohort had a higher mean total Pt concentration in plasma at 24 hours (201.4 ng/mL) than the CP-μD cohort (82.0 ng/ml).
The concentration versus time curve (mean, standard deviation) of the systemically absorbed carboplatin is given as carboplatinplasma (ng/mL) 7 days. ‘●’ indicates the mean of all treatment groups combined.
The pharmacokinetic parameter estimates for total Pt in plasma are presented in Table 1. The pharmacokinetic parameter estimates for the CP and CP-μD cohorts did not significantly differ (p = 0.09). The median (range) total Pt Cmax was 129.4 ng/mL (56.7–349.2 ng/mL) (Table 1). No protein-unbound Pt was detected in any of the plasma samples taken at 168 hours in any rats in either the control or the treatment cohorts.
All muscle samples from the CP treatment cohort (n = 6) contained total Pt [median 268 ng/ml (range 61.7–1083.5 ng/mL)], 6.7 times higher compared to the total Pt in plasma (40ng/ml) in the treatment group (Fig 2). This difference did not reach statistical significance (p = 0.059).
All colonic specimens from all rats were scored ‘0’ for all categories. Inflammation was seen in surgery side wound bed tissue specimens (Fig 3) The median histologic scores for the operated side of the control group were different from zero for inflammation: 2 (range 2–2), necrosis: 1 (range 1–1), and fibrosis 2 (range 2–2) (Table 2). The scores of the operated and the non-operated side were converted to an intra-rat difference [score of the operated side—the score of the non-operated side]. These intra-rat differences are shown in Table 2 for all parameters assessed. The intra-rat difference of the scores did not significantly differ between any of the groups (treatment or control groups) (Table 2).
A Shows a photomicrograph of the subcutaneous perineal surgical implantation site of rat from the CP cohort. Minimal necrosis of adipose (score = 1) (arrow) is present adjacent to the implantation site (asterisk). B Shows a photomicrograph of the subcutaneous perineal surgical implantation site of a rat from the CP-μD cohort. Minimal fibrosis (score = 1) (arrows) is present adjacent to the implantation site (asterisk) after receiving carboplatin and poloxamer 407 gel and a μD catheter (C) at the site.
The first hypothesis of the current study was that carboplatin in poloxamer copolymer gel instilled into the perineal subcutaneous tissues will provide a sustained local presence of carboplatin leading to high local tissue concentrations but low plasma concentrations. We identified prolonged local tissue concentrations of carboplatin, at a higher level than concurrent 168 hour plasma levels. The second hypothesis of the current study was that subcutaneously implanted carboplatin-poloxamer at a concentration of 5mg/ml does not cause local tissue necrosis in the perineal area. We did not identify any gross or histologic evidence of tissue necrosis or wound complications after subcutaneous implantation of 5mg carboplatin in poloxamer 407 in healthy rats, supporting the safety profile of a locally instilled carboplatin in poloxamer copolymer gel into a subcutaneous perineal wound bed.
Overall these results suggest that carboplatin in poloxamer copolymer gel can act as a depot with sustained presence and local release of carboplatin for a minimum of 7 days without major incisional complications or tissue necrosis.
We chose to examine the highest possible local carboplatin concentration that we could instill in the wound as we aimed to examine the toxicity and tissue safety of locally-instilled carboplatin. The amount of 5mg carboplatin in a total volume of 1ml was chosen as the highest concentration of commercially available carboplatin (10mg/ml) that can be added to poloxamer copolymer gel and still allow gelatination of the compound, which would best allow for the assessment of tissue damage in the in vivo portion of the study. A higher ratio of carboplatin to poloxamer copolymer gel was assessed but did not fully convert to a gel state (unpublished data), which would have potentially increased the risk for loss of the compound through the incision line. Due to space limitations in the subcutaneous space, it was not possible to instill more than one ml of carboplatin-poloxamer per rat. Rats in this study therefore received 5mg carboplatin total dose per rat, or approximately 13.3 μg/g BW [= 13 mg/kg BW, or 2.17mg/m2]  carboplatin on Day 0. In comparison, clinically used IV doses of carboplatin are 300 mg/m2 (dogs) and 240–260 mg/m2 (cats)  of which our administered dose falls well below. Total plasma Pt levels rapidly declined after approximately 24 hours (11 rats) or 48 hours (one rat), and were 6.7-fold less than the corresponding muscle tissue Pt levels at 168 hours. No free (unbound) carboplatin was found at 168 hours in the plasma of any of the rats. A prior rodent study using a carboplatin bolus IV of 20 and 30mg/kg, and showed peak plasma concentrations of 13.2 and 31.9 μg/ml within 60 minutes  with a t1/2 of 139.7 and 120.5minutes, respectively. Therefore, there is a possibility that the maximum plasma Pt concentration was reached earlier than 24 hours post-implantation and therefore not captured at the 24hr time point. Daily (q24 hour) sampling points were chosen as, to date, no in vivo absorption data of subcutaneous carboplatin in poloxamer copolymer gel exist. The goal of this study was not to assess the maximum level of systemic absorption, but rather to obtain data on the concentration and duration of local tissue Pt in the wound bed, and to investigate the effects of SC implantation of carboplatin in poloxamer copolymer gel on the local tissues. However, given the results of this study, the addition of more sampling time points within the first 24 hours could allow us to further define the maximum plasma Pt concentration.
The persistent low levels of total plasma Pt concentrations most likely can be attributed to the residual protein bound fraction of carboplatin rather than the continued absorption of the locally implanted carboplatin. Carboplatin has a high % of irreversible protein binding after 24 hours, but it is lower and occurs later than cisplatin protein binding: 90–95% for cisplatin versus 40–50% for carboplatin [26,27] while a different reference cites 85–89% protein binding after 24 hours (www.Medsafe.govt.nz). In addition, the elimination half-life of IV administered carboplatin in rats has been reported to be relatively short at 128±75.7 min  which is in contrast to the prolonged half-life we estimated following SC administration in the poloxamer copolymer gel. Ideally, unbound and bound platinum levels would have been measured at all time points for all rats, but that would have increased the volume of blood needed for sampling which the authors deemed to be unethical given the size of the rats used in this study (0.3ml of blood was taken for each sample in the present study) at all time points.
The median of the measured local tissue total Pt concentrations at 168 hours was 233.7 ng/mL. While the effective in vivo tissue concentration of carboplatin is not known, one in vitro study has found the 72 hour in vitro IC50 of carboplatin for malignant mammary tumors to be 30.5 μM (11.3 μg/mL) , while the IC50 for carboplatin in canine osteosarcoma cell lines was 100 μM  Both of these concentrations are well above the concentrations reached in the present study. No data currently exists for in vivo tumor IC target dose for ASAGAC, nor is any information known regarding the levels of carboplatin necessary to obtain 50% cytotoxicity after 168 hours of exposures in vitro or in vivo. Little is known about tissue concentrations achieved in surgical sites after systemic administration of chemotherapeutics. One previous study has shown that tumoral tissue concentrations after IV administration of 3 mg/kg of cisplatin in mice was 0.84 μg/g after 1hour  While the 168 hour tissue Pt levels found in the current study were below this concentration, we did find prolonged (168 hour) exposure to carboplatin at the site of the wound.
Based on daily wound assessments and clinical appearance, perineal subcutaneous carboplatin instillation in rats using a 5mg/ml concentration, was not associated with tissue necrosis or adverse effects. While it is possible that the histological assessment at 168hrs missed earlier signs of necrosis and/or inflammation, no wound related issues or complications were noted on our daily examination, providing an argument that any potentially missed histological findings were self-limiting and not of clinical relevance.
Subjectively, only a small amount of tension was needed to separate the incision after formalin fixation and skin suture removal, although no dehiscence had been noted in vivo. Unfortunately, we were unable to specifically score for the incision line integrity on histology, as the manipulation from removing the stainless steel sutures and trimming the samples distorted the incisions. Future studies to investigate this subjective finding further could include tensile strength testing on a subset of the specimens, not destined for histological assessment. In addition, while no necrosis was found histologically, the treatment rats did have a higher score for edema in the surgery site. This might be caused by a foreign body reaction (due to the presence of the microdialysis probe), or could be a reaction to the carboplatin that was not severe enough to induce a tissue necrosis or wound healing complications.
The results of the total muscle Pt concentrations suggest that carboplatin in poloxamer copolymer gel could be used in vivo providing direct tissue exposure to carboplatin without significant local effects or systemic absorption. Future in vivo directions should include proof of tissue safety in target species prior to clinical use, in addition to a better understanding of the dose and time of exposure needed by obtaining targeted IC50 data and a more extensive assessment of local tissue Pt concentrations.
Subcutaneous carboplatin in a poloxamer copolymer gel (5 mg/ml) in a perineal location was not associated with clinical adverse effects in an in vivo rodent model, but caution and use of a slow or non-absorbable suture is advised in clinical patients.
S2 File. Raw data for individual Pt assays and histology scoring.
The authors thank Alex Taylor for assistance during the in vitro and in vivo portions of the study.
Submitted & presented in part as an oral research abstract at the 2015 ACVS Surgical Summit, Nashville, TN, October 22-October 24, 2015; Presented in part as a poster at the Duke-NC State Consortium for Canine Comparative Oncology (C3O) symposium, Durham, NC, March 4, 2016.
- 1. Ross JT, Scavelli TD, Mathiesen DT, Patnaik AK. Adenocarcinoma of the apocrine glands of the anal sac in dogs: A review of 32 cases. J Am Anim Hosp Assoc 1991;27:349–355.
- 2. Bennett PF, DeNicola DB, Bonney P, Glickman NW, Knapp DW. Canine anal sac adenocarcinomas: Clinical presentation and response to therapy. J Vet Intern Med 2002;16:100–104. pmid:11822797
- 3. Wouda RM, Borrego J, Keuler NS, Stein T. Evaluation of adjuvant carboplatin chemotherapy in the management of surgically excised anal sac apocrine gland adenocarcinoma in dogs. Vet Comp Oncol 2016;14:67–80. pmid:26811974
- 4. Arthur JJ, Kleiter MM, Thrall DE, Pruitt AF. Characterization of normal tissue complications in 51 dogs undergoing definitive pelvic region irradiation. Vet Radiol Ultrasound 2008;49:85–89. pmid:18251301
- 5. Mathews KG, Linder KE, Davidson GS, Goldman RB, Papich MG. Assessment of clotrimazole gels for in vitro stability and in vivo retention in the frontal sinus of dogs. Am J Vet Res 2009;70:640–647. pmid:19405904
- 6. Sonoda A, Nitta N, Ohta S, Nitta-Seko A, Morikawa S, Tabata Y, et al. Controlled release and antitumor effect of pluronic F127 mixed with cisplatin in a rabbit model. Cardiovasc Intervent Radiol 2010;33:135–142. pmid:19908089
- 7. Zhang K, Shi X, Lin X, Yao C, Shen L, Feng Y. Poloxamer-based in situ hydrogels for controlled delivery of hydrophilic macromolecules after intramuscular injection in rats. Drug Deliv. 2015 May;22(3):375–82. pmid:24601854
- 8. Yu CH, Lee JH, Baek HR, Nam H. The effectiveness of poloxamer 407-based new anti-adhesive material in a laminectomy model in rats. Eur Spine J. 2012 May;21(5):971–10. pmid:22160098
- 9. Kim SY, Chae SW, Lee J. Effect of Poloxamer 407 as a carrier vehicle on rotator cuff healing in a rat model. J Orthop Surg Res. 2014 Mar 1;9(1):12. pmid:24580752
- 10. Risselada M, Marcellin-Little DJ Messenger KM, Griffith E, Davidson GS, Papich MG. In vitro elution of Carboplation from 6 carrier media. Am J Vet Res 2016; 77:1381–1386.
- 11. Emms SG. Anal sac tumours of the dog and their response to cytoreductive surgery and chemotherapy. Aust Vet J 2005;83:340–343. pmid:15986909
- 12. Selmic LE, Burton JH, Thamm DH, Withrow SJ, Lana SE. Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma. J Vet Intern Med 2014;28:554–563. pmid:24512451
- 13. Skorupski KA, Uhl JM, Szivek A, Allstadt Frazier SD, Rebhun RB, Rodriguez CO Jr. Carboplatin versus alternating carboplatin and doxorubicin for the adjuvant treatment of canine appendicular osteosarcoma: A randomized, phase III trial. Vet Comp Oncol 2016;14:81–7. pmid:24118677
- 14. Kozicki AR, Robat C, Chun R, Kurzman ID. Adjuvant therapy with carboplatin and pamidronate for canine appendicular osteosarcoma. Vet Comp Oncol 2015;13:229–236. pmid:23663234
- 15. Simcock JO, Withers SS, Prpich CY, Kuntz CA, Rutland BE. Evaluation of a single subcutaneous infusion of carboplatin as adjuvant chemotherapy for dogs with osteosarcoma: 17 cases (2006–2010). Journal of the American Veterinary Medical Association 2012;241:608–614. pmid:22916858
- 16. Saam DE, Liptak JM, Stalker MJ, et al. Predictors of outcome in dogs treated with adjuvant carboplatin for appendicular osteosarcoma: 65 cases (1996–2006). Journal of the American Veterinary Medical Association 2011;238:195–206. pmid:21235373
- 17. Exner AA, Krupka TM, Scherrer K, Teets JM. Enhancement of carboplatin toxicity by pluronic block copolymers. J Control Release 2005;106:188–197. pmid:15951044
- 18. Hsu YH, Chen DW, Tai CD, Chou YC, Liu SJ, Ueng SW, et al. Biodegradable drug-eluting nanofiber-enveloped implants for sustained release of high bactericidal concentrations of vancomycin and ceftazidime: In vitro and in vivo studies. Int J Nanomedicine 2014;9:4347–4355. pmid:25246790
- 19. Morrison JG, White P, McDougall S, Firth JW, Woolfrey SG, Graham MA, et al. Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids: Application to clinical pharmacokinetic studies with oxaliplatin. J Pharm Biomed Anal 2000;24:1–10. pmid:11108533
- 20. Zamboni WC, Gervais AC, Egorin MJ, Schellens JH, Hamburger DR, Delauter BJ, et al. Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin. Clin Cancer Res 2002;8:2992–2999. pmid:12231546
- 21. Gibaldi M. & Perrier D. (1982) Pharmacokinetics. Marcel Dekker Inc, New York, NY.
- 22. Gabrielsson J.L. & Weiner D.L. (2006) Pharmacokinetic & Pharmacodynamic Data Analysis: Concepts and Applications. Swedish Pharmaceutical Press, Stockholm, Sweden.
- 23. NIH NCIatFrederick [Internet]. Equivalent Surface area dosage conversion factors; [one page]. https://ncifrederick.cancer.gov/lasp/acuc/frederick/Media/Documents/ACUC42.pdf
- 24. Chun R, Garrett LD and Vail DM. Cancer Chemotherapy, in Withrow & MacEwen’s Small Animal Clinical Oncology, 4th edition. Withrow SJ and Vail DM, editors. Saunders Elsevier, St Louis, Missouri, 2007, pp 163–192.
- 25. Johansen MJ, Thapar N, Newman RA, Madden T. Use of microdialysis to study platinum anticancer agent pharmacokinetics in preclinical models. J Exp Ther Oncol 2002;2:163–173. pmid:12415633
- 26. Oguri S, Sakakibara T, Mase H, Shimizu T, Ishikawa K, Kimura K, et al. Clinical pharmacokinetics of carboplatin. J Clin Pharmacol 1988;28:208–215. pmid:3283185
- 27. van der Vijgh WJ. Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet 1991;21:242–261. pmid:1760899
- 28. Simon D, Knebel JW, Baumgartner W, Aufderheide M, Meyer-Lindenberg A, Nolte I. In vitro efficacy of chemotherapeutics as determined by 50% inhibitory concentrations in cell cultures of mammary gland tumors obtained from dogs. Am J Vet Res 2001;62:1825–1830. pmid:11703031
- 29. Holmes KE, Thompson V, Piskun CM, et al. Canine osteosarcoma cell lines from patients with differing serum alkaline phosphatase concentrations display no behavioural differences in vitro. Vet Comp Oncol 2013;13:166–175. pmid:23489774